Skill Checkup: A Menopausal Woman With a Lump in Her Right Breast

Pavani Chalasani, MD, MPH


January 18, 2022

Although many chemotherapy agents and regimens have been studied and used as adjuvant therapy in patients with high-risk early hormone receptor–positive breast cancer, they generally include two of the most active cytotoxic classes of agents in this setting: anthracyclines and taxanes. Many regimens have been evaluated in an effort to achieve highest rates of disease-free and overall survival with the lowest degree of toxicity. Nevertheless, in this setting, some combination of appropriate cytotoxic agents (eg, doxorubicin, cyclophosphamide; paclitaxel or docetaxel) is standard; single-agent treatment (ie, either with 5-fluorouracil or a taxane) is not recommended as adjuvant therapy.

The combination of a platinum agent plus an antifolate, such as cisplatin and pemetrexed, is often used to treat non–small cell lung cancer but is not one of the preferred options for early breast cancer.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.